Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Blincyto

BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion. · Abschnitt 4.8 · PDF-Seite 17

HOS-130854 · Präparat HOS-096973

MedDRA system Very common Common Uncommon organ class (≥ 1/10) (≥ 1/100 to < 1/10) (≥ 1/1 000 to < 1/100) Infections and Bacterial infectionsa, b Sepsis infestations Viral infectionsa, b Pneumonia Infections - pathogen Fungal infectionsa, b unspecifieda, b Blood and lymphatic Febrile neutropenia Leukocytosis5 Lymphadenopathy system disorders Anaemia1 Lymphopenia6 Haemophagocytic Neutropenia2 lymphohistiocytosis Thrombocytopenia3 (HLH) Leukopenia4 Immune system Cytokine release Hypersensitivity Cytokine storm disorders syndromea Metabolism and Tumour lysis syndrome nutrition disorders Psychiatric disordersa Insomnia18 Confusional state18 Disorientation18 Nervous system Headache18 Encephalopathy18 Speech disorder18 disordersa Tremor18 Aphasia18 Paraesthesia18 Seizure18 Cognitive disorder18 Memory impairment Dizziness18 Somnolence18 Hypoaesthesia18 Cranial nerve disorderb Ataxia18 Immune effector cell- associated neurotoxicity syndrome (ICANS) Cardiac disorders Tachycardia7 Vascular disorders Hypotension8 Flushing Capillary leak Hypertension9 syndrome Respiratory, thoracic Cough Dyspnoea Dyspnoea exertional and mediastinal Productive cough Acute respiratory disorders Respiratory failure failure Wheezing Gastrointestinal Nausea Pancreatitisa disorders Diarrhoea Vomiting Constipation Abdominal pain Hepatobiliary Hyperbilirubinaemiaa, 10 disorders

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.